EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL

Remo Panaccione  1     Brian G. Feagan  2     Isabel Redondo  3     Trevor Lissoos  4     Christian Selinger  5     Vipin Arora  4     Milan Lukas  6     Katsuyoshi Matsuoka  7     Toshifumi Hibi  8    
1 University of Calgary, Inflammatory Bowel Disease Center, Calgary, Canada
2 Robarts Clinical Trials Inc, London, Canada
3 Eli Lilly Portugal, Produtos FarmacĂȘuticos, Lda., Lisbon, Portugal
4 Eli Lilly and Company, Indianapolis, Indiana, United States
5 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
6 IBD Clinical and Research Centre, ISCARE Clinical Centre, Prague, Czech Republic
7 Toho University Sakura Medical Center, Sakura, Japan
8 Center for Advanced IBD Research and Treatment, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing